SOHO State of the Art Updates and Next Questions | Next Questions: Acute Lymphoblastic Leukemia

[1]  P. Lu,et al.  Analysis of 60 patients with relapsed or refractory T‐cell acute lymphoblastic leukemia and T‐cell lymphoblastic lymphoma treated with CD7‐targeted chimeric antigen receptor‐T cell therapy , 2023, American journal of hematology/oncology.

[2]  F. Syed,et al.  Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia. , 2023, The New England journal of medicine.

[3]  H. Kantarjian,et al.  A phase II study of hyper-CVAD with blinatumomab (blina) and inotuzumab ozogamicin (INO) for newly diagnosed Philadelphia chromosome (Ph)–negative B-cell acute lymphoblastic leukemia (ALL). , 2023, Journal of Clinical Oncology.

[4]  W. Stock,et al.  Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703. , 2023, Journal of Clinical Oncology.

[5]  A. Logan,et al.  Safety and efficacy of obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19 CAR, in relapsed/refractory adult B-cell acute lymphoblastic leukemia (r/r B-ALL): Top line results of the pivotal FELIX study. , 2023, Journal of Clinical Oncology.

[6]  L. Muffly,et al.  Next-generation sequencing–based MRD in adults with ALL undergoing hematopoietic cell transplantation , 2023, Blood advances.

[7]  K. Patel,et al.  Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT‐PCR for BCR::ABL1 , 2023, American journal of hematology.

[8]  G. Garcia-Manero,et al.  Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia , 2023, Journal of Hematology & Oncology.

[9]  C. Mullighan,et al.  Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements. , 2023, JCO precision oncology.

[10]  H. Kantarjian,et al.  Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. , 2023, The Lancet. Haematology.

[11]  C. Pui,et al.  Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia , 2023, Leukemia.

[12]  Jiecheng Zhang,et al.  Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia , 2023, Journal of Hematology & Oncology.

[13]  F. Ravandi,et al.  The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades , 2023, Journal of Hematology & Oncology.

[14]  C. Mullighan,et al.  Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B‐cell acute lymphoblastic leukemia , 2023, American journal of hematology.

[15]  Xiao-hui Zhang,et al.  CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH Annual Meeting , 2023, Journal of Hematology & Oncology.

[16]  N. Short,et al.  Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past. , 2023, The Lancet. Haematology.

[17]  H. Kantarjian,et al.  First report of PhALLCON: A phase 3 study comparing ponatinib (pon) vs imatinib (im) in newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). , 2023, Journal of Clinical Oncology.

[18]  G. Garcia-Manero,et al.  Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results , 2023, American journal of hematology.

[19]  N. Short,et al.  Evidence-Based Minireview: What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia? , 2022, Hematology. American Society of Hematology. Education Program.

[20]  C. Mullighan,et al.  Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial , 2022, Blood.

[21]  H. Kantarjian,et al.  A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies , 2022, Cancer.

[22]  G. Lenz,et al.  Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial) , 2022, Blood.

[23]  E. Jabbour,et al.  Blinatumomab Alternating With Low-Intensity Chemotherapy (CT) Treatment for Older Adults With Newly Diagnosed Philadelphia (Ph)-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) is Well Tolerated and Efficacious: Safety Run-In Results for the Phase 3 Randomized Controlled Golden Gate , 2022, Blood.

[24]  D. Neuberg,et al.  Nelarabine Combination Therapy for Relapsed or Refractory T-cell Acute Lymphoblastic Lymphoma/Leukemia. , 2022, Blood advances.

[25]  E. Clappier,et al.  Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL): Results of the EWALL-INO Study , 2022, Blood.

[26]  K. Rezvani,et al.  Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. , 2022, The Lancet. Haematology.

[27]  E. Jabbour,et al.  Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia , 2022, Leukemia.

[28]  G. Garcia-Manero,et al.  Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. , 2022, The Lancet. Haematology.

[29]  C. Pui,et al.  Preclinical evaluation of proteolytic targeting of LCK as a therapeutic approach in T cell acute lymphoblastic leukemia , 2022, Science Translational Medicine.

[30]  J. Klco,et al.  Engineering naturally occurring CD7− T cells for the immunotherapy of hematological malignancies , 2022, Blood.

[31]  F. Gao,et al.  The Role of Allogeneic Transplant for Adult Ph+ ALL in CR1 with Complete Molecular Remission: A Retrospective Analysis. , 2022, Blood.

[32]  E. Jabbour,et al.  Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens: A Review. , 2022, JAMA oncology.

[33]  T. Kadia,et al.  P369: A PHASE II STUDY OF MINI-HYPER-CVD PLUS VENETOCLAX IN PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA , 2022, HemaSphere.

[34]  T. Kadia,et al.  P365: INCORPORATION OF NELARABINE (NEL), PEGYLATED ASPARAGINASE (PEG) AND VENETOCLAX (VEN) IN THE FRONTLINE THERAPY OF ADULT PATIENTS WITH T-ACUTE LYMPHOBLASTIC LEUKEMIA/T-LYMPHOBLASTIC LYMPHOMA (T-ALL/LBL) , 2022, HemaSphere.

[35]  R. Foà,et al.  P353: FORTY MONTHS UPDATE OF THE GIMEMA LAL2116 (D-ALBA) PROTOCOL AND ANCILLARY LAL2217 STUDY FOR NEWLY DIAGNOSED ADULT PH+ ALL , 2022, HemaSphere.

[36]  S. Iyer,et al.  Combination therapies to inhibit LCK tyrosine kinase and mTOR signaling in T-cell Acute Lymphoblastic Leukemia. , 2022, Blood.

[37]  M. Konopleva,et al.  High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse , 2022, Blood advances.

[38]  Hui Wang,et al.  Naturally Selected CD7 CAR-T Therapy without Genetic Manipulations for T-ALL/LBL: First-in-human Phase I Clinical Trial. , 2022, Blood.

[39]  B. Wood,et al.  SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  E. Clappier,et al.  Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy Provides Very Good Outcome in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: First Results from the EWALL-INO Study , 2021, Blood.

[41]  F. Pasquier,et al.  Frontline Consolidation with Blinatumomab for High-Risk Philadelphia-Negative Acute Lymphoblastic Adult Patients. Early Results from the Graall-2014-QUEST Phase 2 , 2021, Blood.

[42]  A. Wei,et al.  Sequential Blinatumomab with Reduced Intensity Chemotherapy in the Treatment of Older Adults with Newly Diagnosed Ph Negative B-Precursor Acute Lymphoblastic Leukemia - Interim Analysis of the Australasian Leukemia and Lymphoma Group ALL08 Study , 2021, Blood.

[43]  D. Tichy,et al.  Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with B-Precursor Adult Lymphoblastic Leukemia (ALL): Results of the Ongoing GMALL Bold Trial , 2021, Blood.

[44]  E. Jabbour,et al.  Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms , 2021, Leukemia.

[45]  R. Houot,et al.  KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study , 2021, The Lancet.

[46]  M. Konopleva,et al.  Prognostic factors for progression in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors , 2021, Cancer.

[47]  C. Pui,et al.  Acute lymphoblastic leukemia: A population‐based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980–2017 , 2021, American journal of hematology.

[48]  M. Konopleva,et al.  Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant , 2020, Acta Haematologica.

[49]  R. Foà,et al.  Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. , 2020, The New England journal of medicine.

[50]  David A. Williams,et al.  Toxicity and Response following CD19-specific CAR T cells in pediatric/young adult relapsed/refractory B-ALL. , 2019, Blood.

[51]  H. Heslop,et al.  Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies , 2019, Blood.

[52]  M. Konopleva,et al.  Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. , 2019, Clinical lymphoma, myeloma & leukemia.

[53]  M. Konopleva,et al.  Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysis , 2019, Cancer.

[54]  I. Aldoss,et al.  Acute Lymphoblastic Leukemia in the Older Adult. , 2019, Journal of oncology practice.

[55]  M. Konopleva,et al.  Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. , 2018, The Lancet. Haematology.

[56]  A. Logan,et al.  Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts , 2018, American journal of hematology.

[57]  K. Davis,et al.  Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[58]  Mithat Gonen,et al.  Long‐Term Follow‐up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[59]  M. Konopleva,et al.  Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome‐positive Leukemia , 2017, Clinical lymphoma, myeloma & leukemia.

[60]  D. Berry,et al.  Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis , 2017, JAMA oncology.

[61]  M. Trková,et al.  Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology. , 2017, Blood.

[62]  L. Beppu,et al.  Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[63]  M. Geyer,et al.  Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis. , 2017, Blood.

[64]  W. Klapper,et al.  Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia , 2017, The New England journal of medicine.

[65]  J. Radich,et al.  US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL. , 2016, Blood advances.

[66]  Erika J. Thompson,et al.  Pre-leukemic clonal hematopoiesis and the risk of therapy-related myeloid neoplasms: a case-control study , 2016, The Lancet. Oncology.

[67]  N. Gökbuget.  Treatment of older patients with acute lymphoblastic leukemia. , 2016, Hematology. American Society of Hematology. Education Program.

[68]  J. Cayuela,et al.  Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. , 2016, Blood.

[69]  G. Garcia-Manero,et al.  Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2016, Blood.

[70]  M. Liedtke,et al.  Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. , 2016, The New England journal of medicine.

[71]  M. Konopleva,et al.  Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. , 2016, Blood.

[72]  M. Konopleva,et al.  Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. , 2015, The Lancet. Oncology.

[73]  C. Desmarais,et al.  IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. , 2015, Blood.

[74]  M. Konopleva,et al.  Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia , 2015, Haematologica.

[75]  H. Kantarjian,et al.  Central nervous system prophylaxis in adults with acute lymphoblastic leukemia , 2010, Cancer.

[76]  J. Bourhis,et al.  Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial. , 2002, Blood.

[77]  B. Barlogie,et al.  Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia. , 1988, Blood.